Senseonics Initiates First-in-Human Clinical Study for Freedom CGM System

Article summary

Senseonics Holdings, Inc. has commenced the first-in-human clinical study for its investigational 'Freedom' continuous glucose monitoring (CGM) system, which is designed to operate without an external on-body transmitter.